Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis

[1] Addington D(1990)A depression rating scale for schizophrenics Schizophr Res 3 247-251

[2] Addington J(2012)Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia Eur J Pharmacol 682 1-11

[3] Schissel B(2016)Targeting glutamate to treat schizophrenia: lessons from recent clinical studies Psychopharmacology 233 2425-2428

[4] de Bartolomeis A(2012)Pharmacologic treatment of apathy in dementia Am J Geriatr Psychiatr: Off J Am Assoc Geriatr Psychiatr 20 104-122

[5] Sarappa C(2016)Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: testing an experimental medicine strategy Psychopharmacology 233 2399-2410

[6] Magara S(2007)Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study Schizophr Res 97 294-296

[7] Iasevoli F(2003)The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence Int J Geriatr Psychiatr 18 S23-S32

[8] Beck K(2017)Efficacy of memantine in schizophrenic patients: a systematic review J Amino Acids 2017 7021071-703

[9] Javitt DC(2016)Memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study Acta Med Iran 54 696-198

[10] Howes OD(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-82

[1] Addington D(1990)A depression rating scale for schizophrenics Schizophr Res 3 247-251

[2] Addington J(2012)Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia Eur J Pharmacol 682 1-11

[3] Schissel B(2016)Targeting glutamate to treat schizophrenia: lessons from recent clinical studies Psychopharmacology 233 2425-2428

[4] de Bartolomeis A(2012)Pharmacologic treatment of apathy in dementia Am J Geriatr Psychiatr: Off J Am Assoc Geriatr Psychiatr 20 104-122

[5] Sarappa C(2016)Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: testing an experimental medicine strategy Psychopharmacology 233 2399-2410

[6] Magara S(2007)Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study Schizophr Res 97 294-296

[7] Iasevoli F(2003)The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence Int J Geriatr Psychiatr 18 S23-S32

[8] Beck K(2017)Efficacy of memantine in schizophrenic patients: a systematic review J Amino Acids 2017 7021071-703

[9] Javitt DC(2016)Memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study Acta Med Iran 54 696-198

[10] Howes OD(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-82